The management of breast cancer

Diagnostic and Interventional Imaging

Volumn 95, Issue 7-8, 2014, Pages 753-757

  Espie M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast; Neoadjuvant; Targeted therapy; Triple negative; Tumor

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; LAPATINIB; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; ARTHRALGIA; BONE DENSITY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CATARACT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; DEPRESSION; ENDOMETRIUM CANCER; FATIGUE; FEVER; FRACTURE; FRANCE; HEPATITIS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LEUKEMIA; LEUKORRHEA; LIBIDO DISORDER; MAMMOGRAPHY; MASTECTOMY; MOLECULARLY TARGETED THERAPY; MYALGIA; PARESTHESIA; PLASTIC SURGERY; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRIPLE NEGATIVE BREAST CANCER; VAGINAL DRYNESS; WEAKNESS; WEIGHT GAIN; BREAST NEOPLASMS; FEMALE; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PROGNOSIS;

EID: 84906939381     PISSN: None     EISSN: 22115684     Source Type: Journal    
DOI: 10.1016/j.diii.2014.04.003     Document Type: Short Survey

References (16)

1. Esteve J. Incidence of breast cancer in France and other indus-trialized countries. Presse Med 2007;36(2 Pt 2):315-21.
2. Trétarre B, Guizard AV, Fontaine D, et al. Cancer du seinchez la femme: incidence et mortalité, France 2000. BEH2004;44:209-10.
3. Hindie E, Groheux D, Brenot-Rossi I, Rubello D, Moretti JL,Espie M. The sentinel node procedure in breast cancer: nuclearmedicine as the starting point. J Nucl Med 2011;52(3):405-14.
4. Hildreth NG, Kelsey JL, LiVolsi VA, Fischer DB, Holford TR,Mostow ED, et al. An epidemiologic study of epithelial carci-noma of the ovary. Am J Epidemiol 1981;114(3):398-405.
5. Lepage C, Lantieri L. Breast reconstruction after mastectomy.Rev Prat 2010;60(9):1221-6.
6. Jacquin JP, Jones S, Magne N, Chapelle C, Ellis P, Janni W, et al.Docetaxel-containing adjuvant chemotherapy in patients withearly stage breast cancer. Consistency of effect independentof nodal and biomarker status: a meta-analysis of 14 ran-domized clinical trials. Breast Cancer Res Treat 2012;134(3):903-13.
7. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M,et al. Comparisons between different polychemotherapy regi-mens for early breast cancer: meta-analyses of long-termoutcome among 100,000 women in 123 randomised trials.Lancet 2012;379(9814):432-44.
8. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adju-vant treatment of HER2-positive early breast cancer patients: ameta-analysis of published randomized controlled trials. PLoSOne 2011;6(6):e21030.
9. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J,et al. Meta-analysis of breast cancer outcomes in adjuvanttrials of aromatase inhibitors versus tamoxifen. J Clin Oncol2010;28(3):509-18.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breastcancer on recurrence and 15-year survival: an overview of therandomised trials. Lancet 2005;365(9472):1687-717.
11. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity ofadjuvant endocrine therapy in postmenopausal breast cancerpatients: a systematic review and meta-analysis. J Natl CancerInst 2009;103(17):1299-309.
12. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML,Mamounas E. Meta-analysis of the association of breast can-cer subtype and pathologic complete response to neoadjuvantchemotherapy. Eur J Cancer 2012;48(18):3342-54.
13. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Per-tuzumab plus trastuzumab plus docetaxel for metastatic breastcancer. N Engl J Med 2012;366(2):109-19.
14. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de AzambujaE, Aura C, et al. Lapatinib with trastuzumab for HER2-positiveearly breast cancer (NeoALTTO): a randomised, open-label,multicentre, phase 3 trial. Lancet 2012;379(9816):633- 40.
15. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al.Trastuzumab emtansine for HER2-positive advanced breastcancer. N Engl J Med 2012;367(19):1783-91.
16. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS,Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med2012;366(6):520-9.